Nektar Therapeutics - Articles and news items

Nektar’s opioid analgesic meets endpoints in Phase 3 Study of chronic pain

Industry news / 28 March 2017 / Niamh Marriott, Junior Editor

Nektar Therapeutics announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181, an opioid analgesic…

Bristol-Myers Squibb and Nektar Therapeutics to combine oncology therapies

Industry news / 28 September 2016 / Niamh Louise Marriott, Digital Content Producer

Bristol-Myers’ Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression and NKTR-214 is an immuno-stimulatory therapy…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+